hoge/10242
更新日: 2015-10-30 (金) 13:15:05 (3101d)
I study here <a href=" http://transformando.org/thunderscream-drops.pptx ">is thunderscream safe</a> Amgen earlier this year approached Onyx with an offer of $120 a share for the company, whose primary attraction is a blood-cancer drug called Kyprolis. Onyx then tried to run an auction to get a better price, but ultimately appears to have been unable to find another party to pay more than Amgen in an acceptable time frame. 
- ページ: hoge
- 投稿者: Crazyfrog?
- 優先順位: ä½
- 状態: çæ
- カテゴリー: 1393043320
- 投稿日: 2015-10-30 (金) 13:15:05
- バージョン: 6
メッセージ
I study here <a href=" http://transformando.org/thunderscream-drops.pptx ">is thunderscream safe</a> Amgen earlier this year approached Onyx with an offer of $120 a share for the company, whose primary attraction is a blood-cancer drug called Kyprolis. Onyx then tried to run an auction to get a better price, but ultimately appears to have been unable to find another party to pay more than Amgen in an acceptable time frame.
- このページを共有：
-
このページのURL：
